V Cox1, G Brigden2, R H Crespo3, E Lessem4, S Lynch5, M L Rich6, B Waning3, J Furin7. 1. Drug-Resistant TB Scale-Up Treatment Action Team, Global Drug-Resistant Tuberculosis Initiative, Stop TB Partnership, Geneva, Switzerland, Center for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa. 2. International Union Against Tuberculosis and Lung Disease, Geneva. 3. Global Drug Facility, Stop TB Partnership, Geneva, Switzerland. 4. Treatment Action Group, New York, New York. 5. Médecins Sans Frontières Access Campaign, New York, New York. 6. Partners In Health, Boston, Massachusetts, Brigham and Women's Hospital, Boston, Massachusetts. 7. Partners In Health, Boston, Massachusetts, Harvard Medical School, Boston, Massachusetts, USA.
Abstract
SETTING: The World Health Organization recommended two new drugs, bedaquiline (BDQ) and delamanid (DLM), for the treatment of multidrug-resistant tuberculosis (MDR-TB) in 2013 and 2014, respectively. An estimated one third of patients with MDR-TB would benefit from the inclusion of these drugs in their treatment regimens. DESIGN: A convenience sample of 36 countries voluntarily reported monthly data on cumulative programmatic use of new drugs to the Drug-Resistant TB Scale-Up Treatment Action Team between 1 July 2015 and 31 June 2017. Programmatic use was defined as treatment for MDR-TB with newer drugs outside of clinical trials or compassionate use. RESULTS: A total of 10 164 persons were started on BDQ and 688 started on DLM during the reporting period. Only 15.7% of the 69 213 persons estimated to need newer drugs over the study period were reported to have received them. CONCLUSION: While there has been significant progress in some countries, uptake of the newer drugs has not kept pace with a conservative estimate of need; fewer than 20% of persons likely to benefit from either BDQ or DLM have received them. Concerted efforts are needed to ensure that the newer drugs are made available more widely for persons with MDR-TB in need of these therapeutic options.
SETTING: The World Health Organization recommended two new drugs, bedaquiline (BDQ) and delamanid (DLM), for the treatment of multidrug-resistant tuberculosis (MDR-TB) in 2013 and 2014, respectively. An estimated one third of patients with MDR-TB would benefit from the inclusion of these drugs in their treatment regimens. DESIGN: A convenience sample of 36 countries voluntarily reported monthly data on cumulative programmatic use of new drugs to the Drug-Resistant TB Scale-Up Treatment Action Team between 1 July 2015 and 31 June 2017. Programmatic use was defined as treatment for MDR-TB with newer drugs outside of clinical trials or compassionate use. RESULTS: A total of 10 164 persons were started on BDQ and 688 started on DLM during the reporting period. Only 15.7% of the 69 213 persons estimated to need newer drugs over the study period were reported to have received them. CONCLUSION: While there has been significant progress in some countries, uptake of the newer drugs has not kept pace with a conservative estimate of need; fewer than 20% of persons likely to benefit from either BDQ or DLM have received them. Concerted efforts are needed to ensure that the newer drugs are made available more widely for persons with MDR-TB in need of these therapeutic options.
Authors: Afsatou Ndama Traoré; Mpumelelo Casper Rikhotso; Ntshuxeko Thelma Banda; Maphepele Sara Mashilo; Jean Pierre Kabue Ngandu; Vuyo Mavumengwana; Andre G Loxton; Craig Kinnear; Natasha Potgieter; Scott Heysell; Rob Warren Journal: Pathogens Date: 2022-06-01
Authors: R R Kempker; L Mikiashvili; Y Zhao; D Benkeser; K Barbakadze; N Bablishvili; Z Avaliani; C A Peloquin; H M Blumberg; M Kipiani Journal: Clin Infect Dis Date: 2020-12-03 Impact factor: 9.079
Authors: M Taune; P Ustero; S Hiashiri; K Huang; P Aia; L Morris; S Main; G Chan; P du Cros; S S Majumdar Journal: Public Health Action Date: 2019-09-21
Authors: André N H Bulabula; Jenna A Nelson; Eric M Musafiri; Rhoderick Machekano; Nadia A Sam-Agudu; Andreas H Diacon; Maunank Shah; Jacob Creswell; Grant Theron; Robin M Warren; Karen R Jacobson; Jean-Paul Chirambiza; Dieudonné Kalumuna; Bertin C Bisimwa; Patrick D M C Katoto; Michel K Kaswa; Freddy M Birembano; Liliane Kitete; Martin P Grobusch; Zacharie M Kashongwe; Jean B Nachega Journal: Clin Infect Dis Date: 2019-09-27 Impact factor: 9.079
Authors: Sergo A Vashakidze; Shota G Gogishvili; Ketino G Nikolaishvili; Zaza R Avaliani; Abivarma Chandrakumaran; Giorgi Sh Gogishvili; Mathew Magee; Henry M Blumberg; Russell R Kempker Journal: Eur J Cardiothorac Surg Date: 2021-12-01 Impact factor: 4.534
Authors: Jeremiah Chakaya; Mishal Khan; Francine Ntoumi; Eleni Aklillu; Razia Fatima; Peter Mwaba; Nathan Kapata; Sayoki Mfinanga; Seyed Ehtesham Hasnain; Patrick D M C Katoto; André N H Bulabula; Nadia A Sam-Agudu; Jean B Nachega; Simon Tiberi; Timothy D McHugh; Ibrahim Abubakar; Alimuddin Zumla Journal: Int J Infect Dis Date: 2021-03-11 Impact factor: 3.623